EBITDA for Amgen (AMGN)
According to Amgen's latest reported financial statements, the company's current EBITDA (TTM) is $18.69B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
AMGN
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$18.69B
YoY change
+18.6%
5Y CAGR
+4.0%
Peak year (2025)
$15.84B
Cumulative EBITDA
$232.19B
EBITDA history chart for Amgen (AMGN) from 1985 to 2025
EBITDA history table for Amgen (AMGN) from 1985 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $15.84B | +18.6% | ||
| 2024 | $13.36B | -9.8% | ||
| 2023 | $14.80B | +21.6% | ||
| 2022 | $12.17B | +7.7% | ||
| 2021 | $11.30B | -13.1% | ||
| 2020 | $13.00B | +2.9% | ||
| 2019 | $12.63B | -1.9% | ||
| 2018 | $12.88B | +0.2% | ||
| 2017 | $12.86B | +2.6% | ||
| 2016 | $12.53B | +12.0% | ||
| 2015 | $11.18B | +27.8% | ||
| 2014 | $8.75B | +15.5% | ||
| 2013 | $7.57B | +5.9% | ||
| 2012 | $7.15B | +22.9% | ||
| 2011 | $5.82B | -16.1% | ||
| 2010 | $6.94B | +1.6% | ||
| 2009 | $6.83B | +2.9% | ||
| 2008 | $6.64B | +11.0% | ||
| 2007 | $5.98B | -0.9% | ||
| 2006 | $6.03B | +6.1% | ||
| 2005 | $5.69B | +22.7% | ||
| 2004 | $4.64B | +22.7% | ||
| 2003 | $3.78B | +42.4% | ||
| 2002 | $2.65B | +47.7% | ||
| 2001 | $1.80B | +13.7% | ||
| 2000 | $1.58B | +5.2% | ||
| 1999 | $1.50B | +19.0% | ||
| 1998 | $1.26B | +20.5% | ||
| 1997 | $1.05B | +3.1% | ||
| 1996 | $1.02B | +20.3% | ||
| 1995 | $845.00M | +9.3% | ||
| 1994 | $773.00M | +28.4% | ||
| 1993 | $601.90M | +13.2% | ||
| 1992 | $531.70M | +266.9% | ||
| 1991 | $144.90M | +110.6% | ||
| 1990 | $68.80M | — | ||
| 1988 | $3.20M | -313.3% | ||
| 1987 | -$1.50M | -225.0% | ||
| 1986 | $1.20M | -25.0% | ||
| 1985 | $1.60M | — |
EBITDA values are taken from Amgen's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Amgen (AMGN) most recent annual EBITDA stands at $15.84B (2025) – grew 18.6% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Amgen EBITDA compounded at +4.0% per year, with the latest reading among the more recent periods of the dataset.
Across the available history, EBITDA reached its high of $15.84B in 2025 and its low of -$1.50M in 1987.
Within Healthcare, Amgen (AMGN) ranks 8th among 8 peers we track. The peer median for EBITDA is $24.21B.
Amgen EBITDA by Year
Amgen EBITDA 2025: $15.84B
Amgen EBITDA in 2025 was $15.84B, grew 18.6% from 2024. This figure represents the highest annual value in the available history.
Amgen EBITDA 2024: $13.36B
Amgen EBITDA in 2024 was $13.36B, declined 9.8% below 2023.
Amgen EBITDA 2023: $14.80B
Amgen EBITDA in 2023 was $14.80B, grew 21.6% from 2022.
Amgen EBITDA 2022: $12.17B
Amgen EBITDA in 2022 was $12.17B, grew 7.7% from 2021.
Amgen EBITDA 2021: $11.30B
Amgen EBITDA in 2021 was $11.30B.
See more financial history for Amgen (AMGN).
Sector peers — EBITDA
Companies in the same sector as Amgen, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $11.47B | Healthcare |
Frequently asked questions
What is Amgen's EBITDA?
- Latest reported EBITDA for Amgen (AMGN) is $18.69B (period ending December 31, 2025).
How has Amgen EBITDA changed year-over-year?
- Amgen (AMGN) EBITDA changed +18.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Amgen EBITDA?
- Amgen (AMGN) EBITDA compound annual growth rate is +4.0% over the most recent 5 years available.
When did Amgen EBITDA hit its highest annual value?
- Amgen EBITDA reached its highest annual value of $15.84B in 2025.
What was Amgen EBITDA in 2024?
- Amgen (AMGN) EBITDA in 2024 was $13.36B.
What was Amgen EBITDA in 2025?
- Amgen (AMGN) EBITDA in 2025 was $15.84B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
AMGN Overview
Company profile, financial tools, and key metrics
AMGN Revenue Counter
Earns $1,166 every second. See per minute, hour, and day.
AMGN Earnings Counter
Earns $244.51 per second net profit. See per minute, hour, and day.
AMGN Economic Scale
Exceeds El Salvador's GDP. Compare with world economies.
AMGN What If Invested
What if you had invested $1,000? See historical returns from any date.
AMGN How It Makes Money
Discover visual breakdown of $36.77B in revenue — where it comes from and where it goes.
AMGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AMGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AMGN Daily Price Character
Balanced · 48.1% historical win rate (green days). Streaks & record days.
AMGN Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
AMGN Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
AMGN Dividend Profile
Yield: 2.86%. Safety: 8/8. See full history.
AMGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AMGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.